Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (EP3087086) CRYSTALLINE FORMS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE

Office : European Patent Office
Application Number: 14824322 Application Date: 18.12.2014
Publication Number: 3087086 Publication Date: 02.11.2016
Publication Kind : B1
Designated States: AL,AT,BA,BE,BG,CH,CY,CZ,DE,DK,EE,ES,FI,FR,GB,GR,HR,HU,IE,IS,IT,LI,LT,LU,LV,MC,ME,MK,MT,NL,NO,PL,PT,RO,RS,SE,SI,SK,SM,TR
Prior PCT appl.: Application Number:US2014071310 ; Publication Number: Click to see the data
IPC:
C07K 5/12
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
5
Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof
04
containing only normal peptide links
12
Cyclic peptides
CPC:
C07D 498/16
A61K 31/4985
A61K 45/06
C07K 5/0808
Applicants: GILEAD SCIENCES INC
Inventors: BRINGLEY DUSTIN
CHAN JOHANN
FUNG PETER
KEATON KATIE
LAPINA OLGA
MORRISON HENRY
PCION DOMINIKA
Priority Data: 201361920427 23.12.2013 US
2014071310 18.12.2014 US
Title: (DE) KRISTALLINE FORMEN EINES MAKROCYCLISCHEN HCV-NS3-HEMMENDEN TRIPEPTIDS
(EN) CRYSTALLINE FORMS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE
(FR) FORMES CRISTALLINES D'UN COMPOSÉ ANTIVIRAL
Abstract: front page image
(EN) Crystalline forms of the anti-HCV compound (1R,5S,8S,9S,10R,22aR )-5-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-9-ethyl-18,18-difluoro-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6] dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide (Compound I) were prepared and characterized in the solid state. Also provided are processes of manufacture and methods of using the crystalline forms.
(FR) Formes cristallines du composé anti-VHC (1aR,5S,8S,9S,10R,22aR )-5-tert-butyl-N-[(1R,2R)-2-(difluorométhyl)-1-{[(1-méthylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-9-éthyl-18,18-difluoro-14-méthoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tétradécahydro-8H-7,10-méthanocyclopropa[18,19][1,10,3,6] dioxadiazacyclononadécino[11,12-b]quinoxaline-8-carboxamide (composé I) qui ont été préparées et qui sont caractérisées à l'état solide. L'invention concerne également des procédés de fabrication et des procédés d'utilisation desdites formes cristallines.
Also published as:
UY0001035918CA2934049JP2017503016AU2014370124ES2708993WO/2015/100144